BioSpace News Archive

February 8 Research Roundup: Fasting Metabolism, Conflicting p53 Protein Data, and the Gene Behind Sleeping in Response to Illness

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

February 7, 2019

·

6 min read

·

Mark Terry

Drug Development

Interview: Clinical Trial Transparency Is Improving, Particularly Among Larger Companies

Thomas Wicks, chief strategy officer of New Jersey-based TrialScope, said transparency has picked up over the past few years, particularly as large pharma companies have begun to release information about their own clinical efforts.

February 7, 2019

·

3 min read

·

Alex Keown

Career Advice

Is the Traditional Job Interview About to Get a Much-Needed Makeover?

An new innovative approach to the job interview, and one that could catch on in industries outside of tech.

February 7, 2019

·

3 min read

·

BioSpace Staff

FDA

Medtronic Receives FDA Approval on Expanded Indication for Pipeline Flex Embolization Device

Approval Based on Clinical Data from the PREMIER Trial - New Indication Provides Options for Patients with Small or Medium, Wide-Necked Brain Aneurysms

February 7, 2019

·

4 min read

BioForest

Report Shows Life Science Companies Continue to Be a Favorite Target of Securities Fraud Class Action Lawsuits

Despite a decline over the past year of class-action lawsuits, life science companies remain a popular target for securities fraud litigation.

February 7, 2019

·

2 min read

·

Alex Keown

Business

Invitation to presentation of BioArctic’s Full Year Report 2018 on February 14, 2019

BioArctic AB to publish the company’s Full Year Report for the period January – December 2018 on Thursday, February 14, 2019 at 08:00 a.m. CET.

February 7, 2019

·

1 min read

Drug Development

Adrenomed AG announces publication of Phase II trial design of Adrecizumab to treat septic shock

Ongoing proof-of-concept trial AdrenOSS-II testing Adrecizumab in early septic shock

February 7, 2019

·

4 min read

Policy

Pharma Leaders Draw Line in the Sand and Back HHS Rebate Plan

After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the proposal.

February 7, 2019

·

3 min read

·

Alex Keown

Business

HiberCell Launches With $60.75 Million Series A to Target Dormant Metastatic Cancer Cells

Recurrence of cancer, which is the cause of many cancer deaths, is driven by dormant disseminated tumor cells (DTCs) that remain undetected in the body for long periods of time. HiberCell is working to develop first-in-class drugs that target DTCs that originate from solid and liquid tumors.

February 7, 2019

·

3 min read

·

Mark Terry

FDA

Sanofi Snags FDA Approval for Rare Blood Disorder

The U.S. Food and Drug Administration approved the first treatment for acquired thrombotic thrombocytopenic purpura (aTTP). Sanofi’s Cablivi was given the greenlight and will become a cornerstone of the company’s new rare blood disorders franchise.

February 7, 2019

·

2 min read

·

Alex Keown